Cargando…
The humanised CYP2C19 transgenic mouse exhibits cerebellar atrophy and movement impairment reminiscent of ataxia
AIMS: CYP2C19 transgenic mouse expresses the human CYP2C19 gene in the liver and developing brain, and it exhibits altered neurodevelopment associated with impairments in emotionality and locomotion. Because the validation of new animal models is essential for the understanding of the aetiology and...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108232/ https://www.ncbi.nlm.nih.gov/pubmed/36536486 http://dx.doi.org/10.1111/nan.12867 |
_version_ | 1785026806571597824 |
---|---|
author | Milosavljević, Filip Brusini, Irene Atanasov, Andrea Manojlović, Marina Vučić, Marija Oreščanin‐Dušić, Zorana Brkljačić, Jelena Miljević, Čedo Nikolić‐Kokić, Aleksandra Blagojević, Duško Wang, Chunliang Damberg, Peter Pešić, Vesna Tyndale, Rachel F. Ingelman‐Sundberg, Magnus Jukić, Marin M. |
author_facet | Milosavljević, Filip Brusini, Irene Atanasov, Andrea Manojlović, Marina Vučić, Marija Oreščanin‐Dušić, Zorana Brkljačić, Jelena Miljević, Čedo Nikolić‐Kokić, Aleksandra Blagojević, Duško Wang, Chunliang Damberg, Peter Pešić, Vesna Tyndale, Rachel F. Ingelman‐Sundberg, Magnus Jukić, Marin M. |
author_sort | Milosavljević, Filip |
collection | PubMed |
description | AIMS: CYP2C19 transgenic mouse expresses the human CYP2C19 gene in the liver and developing brain, and it exhibits altered neurodevelopment associated with impairments in emotionality and locomotion. Because the validation of new animal models is essential for the understanding of the aetiology and pathophysiology of movement disorders, the objective was to characterise motoric phenotype in CYP2C19 transgenic mice and to investigate its validity as a new animal model of ataxia. METHODS: The rotarod, paw‐print and beam‐walking tests were utilised to characterise the motoric phenotype. The volumes of 20 brain regions in CYP2C19 transgenic and wild‐type mice were quantified by 9.4T gadolinium‐enhanced post‐mortem structural neuroimaging. Antioxidative enzymatic activity was quantified biochemically. Dopaminergic alterations were characterised by chromatographic quantification of concentrations of dopamine and its metabolites and by subsequent immunohistochemical analyses. The beam‐walking test was repeated after the treatment with dopamine receptor antagonists ecopipam and raclopride. RESULTS: CYP2C19 transgenic mice exhibit abnormal, unilateral ataxia‐like gait, clasping reflex and 5.6‐fold more paw‐slips in the beam‐walking test; the motoric phenotype was more pronounced in youth. Transgenic mice exhibited a profound reduction of 12% in cerebellar volume and a moderate reduction of 4% in hippocampal volume; both regions exhibited an increased antioxidative enzyme activity. CYP2C19 mice were hyperdopaminergic; however, the motoric impairment was not ameliorated by dopamine receptor antagonists, and there was no alteration in the number of midbrain dopaminergic neurons in CYP2C19 mice. CONCLUSIONS: Humanised CYP2C19 transgenic mice exhibit altered gait and functional motoric impairments; this phenotype is likely caused by an aberrant cerebellar development. |
format | Online Article Text |
id | pubmed-10108232 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101082322023-04-18 The humanised CYP2C19 transgenic mouse exhibits cerebellar atrophy and movement impairment reminiscent of ataxia Milosavljević, Filip Brusini, Irene Atanasov, Andrea Manojlović, Marina Vučić, Marija Oreščanin‐Dušić, Zorana Brkljačić, Jelena Miljević, Čedo Nikolić‐Kokić, Aleksandra Blagojević, Duško Wang, Chunliang Damberg, Peter Pešić, Vesna Tyndale, Rachel F. Ingelman‐Sundberg, Magnus Jukić, Marin M. Neuropathol Appl Neurobiol Original Articles AIMS: CYP2C19 transgenic mouse expresses the human CYP2C19 gene in the liver and developing brain, and it exhibits altered neurodevelopment associated with impairments in emotionality and locomotion. Because the validation of new animal models is essential for the understanding of the aetiology and pathophysiology of movement disorders, the objective was to characterise motoric phenotype in CYP2C19 transgenic mice and to investigate its validity as a new animal model of ataxia. METHODS: The rotarod, paw‐print and beam‐walking tests were utilised to characterise the motoric phenotype. The volumes of 20 brain regions in CYP2C19 transgenic and wild‐type mice were quantified by 9.4T gadolinium‐enhanced post‐mortem structural neuroimaging. Antioxidative enzymatic activity was quantified biochemically. Dopaminergic alterations were characterised by chromatographic quantification of concentrations of dopamine and its metabolites and by subsequent immunohistochemical analyses. The beam‐walking test was repeated after the treatment with dopamine receptor antagonists ecopipam and raclopride. RESULTS: CYP2C19 transgenic mice exhibit abnormal, unilateral ataxia‐like gait, clasping reflex and 5.6‐fold more paw‐slips in the beam‐walking test; the motoric phenotype was more pronounced in youth. Transgenic mice exhibited a profound reduction of 12% in cerebellar volume and a moderate reduction of 4% in hippocampal volume; both regions exhibited an increased antioxidative enzyme activity. CYP2C19 mice were hyperdopaminergic; however, the motoric impairment was not ameliorated by dopamine receptor antagonists, and there was no alteration in the number of midbrain dopaminergic neurons in CYP2C19 mice. CONCLUSIONS: Humanised CYP2C19 transgenic mice exhibit altered gait and functional motoric impairments; this phenotype is likely caused by an aberrant cerebellar development. John Wiley and Sons Inc. 2023-01-17 2023-02 /pmc/articles/PMC10108232/ /pubmed/36536486 http://dx.doi.org/10.1111/nan.12867 Text en © 2022 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd on behalf of British Neuropathological Society. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Milosavljević, Filip Brusini, Irene Atanasov, Andrea Manojlović, Marina Vučić, Marija Oreščanin‐Dušić, Zorana Brkljačić, Jelena Miljević, Čedo Nikolić‐Kokić, Aleksandra Blagojević, Duško Wang, Chunliang Damberg, Peter Pešić, Vesna Tyndale, Rachel F. Ingelman‐Sundberg, Magnus Jukić, Marin M. The humanised CYP2C19 transgenic mouse exhibits cerebellar atrophy and movement impairment reminiscent of ataxia |
title | The humanised CYP2C19 transgenic mouse exhibits cerebellar atrophy and movement impairment reminiscent of ataxia |
title_full | The humanised CYP2C19 transgenic mouse exhibits cerebellar atrophy and movement impairment reminiscent of ataxia |
title_fullStr | The humanised CYP2C19 transgenic mouse exhibits cerebellar atrophy and movement impairment reminiscent of ataxia |
title_full_unstemmed | The humanised CYP2C19 transgenic mouse exhibits cerebellar atrophy and movement impairment reminiscent of ataxia |
title_short | The humanised CYP2C19 transgenic mouse exhibits cerebellar atrophy and movement impairment reminiscent of ataxia |
title_sort | humanised cyp2c19 transgenic mouse exhibits cerebellar atrophy and movement impairment reminiscent of ataxia |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108232/ https://www.ncbi.nlm.nih.gov/pubmed/36536486 http://dx.doi.org/10.1111/nan.12867 |
work_keys_str_mv | AT milosavljevicfilip thehumanisedcyp2c19transgenicmouseexhibitscerebellaratrophyandmovementimpairmentreminiscentofataxia AT brusiniirene thehumanisedcyp2c19transgenicmouseexhibitscerebellaratrophyandmovementimpairmentreminiscentofataxia AT atanasovandrea thehumanisedcyp2c19transgenicmouseexhibitscerebellaratrophyandmovementimpairmentreminiscentofataxia AT manojlovicmarina thehumanisedcyp2c19transgenicmouseexhibitscerebellaratrophyandmovementimpairmentreminiscentofataxia AT vucicmarija thehumanisedcyp2c19transgenicmouseexhibitscerebellaratrophyandmovementimpairmentreminiscentofataxia AT orescanindusiczorana thehumanisedcyp2c19transgenicmouseexhibitscerebellaratrophyandmovementimpairmentreminiscentofataxia AT brkljacicjelena thehumanisedcyp2c19transgenicmouseexhibitscerebellaratrophyandmovementimpairmentreminiscentofataxia AT miljeviccedo thehumanisedcyp2c19transgenicmouseexhibitscerebellaratrophyandmovementimpairmentreminiscentofataxia AT nikolickokicaleksandra thehumanisedcyp2c19transgenicmouseexhibitscerebellaratrophyandmovementimpairmentreminiscentofataxia AT blagojevicdusko thehumanisedcyp2c19transgenicmouseexhibitscerebellaratrophyandmovementimpairmentreminiscentofataxia AT wangchunliang thehumanisedcyp2c19transgenicmouseexhibitscerebellaratrophyandmovementimpairmentreminiscentofataxia AT dambergpeter thehumanisedcyp2c19transgenicmouseexhibitscerebellaratrophyandmovementimpairmentreminiscentofataxia AT pesicvesna thehumanisedcyp2c19transgenicmouseexhibitscerebellaratrophyandmovementimpairmentreminiscentofataxia AT tyndalerachelf thehumanisedcyp2c19transgenicmouseexhibitscerebellaratrophyandmovementimpairmentreminiscentofataxia AT ingelmansundbergmagnus thehumanisedcyp2c19transgenicmouseexhibitscerebellaratrophyandmovementimpairmentreminiscentofataxia AT jukicmarinm thehumanisedcyp2c19transgenicmouseexhibitscerebellaratrophyandmovementimpairmentreminiscentofataxia AT milosavljevicfilip humanisedcyp2c19transgenicmouseexhibitscerebellaratrophyandmovementimpairmentreminiscentofataxia AT brusiniirene humanisedcyp2c19transgenicmouseexhibitscerebellaratrophyandmovementimpairmentreminiscentofataxia AT atanasovandrea humanisedcyp2c19transgenicmouseexhibitscerebellaratrophyandmovementimpairmentreminiscentofataxia AT manojlovicmarina humanisedcyp2c19transgenicmouseexhibitscerebellaratrophyandmovementimpairmentreminiscentofataxia AT vucicmarija humanisedcyp2c19transgenicmouseexhibitscerebellaratrophyandmovementimpairmentreminiscentofataxia AT orescanindusiczorana humanisedcyp2c19transgenicmouseexhibitscerebellaratrophyandmovementimpairmentreminiscentofataxia AT brkljacicjelena humanisedcyp2c19transgenicmouseexhibitscerebellaratrophyandmovementimpairmentreminiscentofataxia AT miljeviccedo humanisedcyp2c19transgenicmouseexhibitscerebellaratrophyandmovementimpairmentreminiscentofataxia AT nikolickokicaleksandra humanisedcyp2c19transgenicmouseexhibitscerebellaratrophyandmovementimpairmentreminiscentofataxia AT blagojevicdusko humanisedcyp2c19transgenicmouseexhibitscerebellaratrophyandmovementimpairmentreminiscentofataxia AT wangchunliang humanisedcyp2c19transgenicmouseexhibitscerebellaratrophyandmovementimpairmentreminiscentofataxia AT dambergpeter humanisedcyp2c19transgenicmouseexhibitscerebellaratrophyandmovementimpairmentreminiscentofataxia AT pesicvesna humanisedcyp2c19transgenicmouseexhibitscerebellaratrophyandmovementimpairmentreminiscentofataxia AT tyndalerachelf humanisedcyp2c19transgenicmouseexhibitscerebellaratrophyandmovementimpairmentreminiscentofataxia AT ingelmansundbergmagnus humanisedcyp2c19transgenicmouseexhibitscerebellaratrophyandmovementimpairmentreminiscentofataxia AT jukicmarinm humanisedcyp2c19transgenicmouseexhibitscerebellaratrophyandmovementimpairmentreminiscentofataxia |